BioCardia announces the issuance of two patents on biotherapeutic delivery to the heart
April 27, 2004 (Press Release) --
South San Francisco, CA., April 26th 2004
BioCardia, Inc. announces the issuance of US Patent No. 6,726,654 entitled “System and method for delivering thermally sensitive and reverse-thermal gelation materials”. The patent, describes systems and methods for the delivery of controlled release polymers which change viscosity at different temperature enabling their delivery through catheters in an interventional setting.
BioCardia also announces the issuance of US Patent No. 6,726,242 entitled “Catheter Drug Delivery System and Method for Use”. The patent, describes a means to trigger delivery of a set amount of a therapeutic agent from within a chamber of the heart to a target site in the heart of a patient.
BioCardia is a world leader in the emerging field of biointerventional cardiology, developing locally delivered biotechnology product solutions for patients suffering from heart failure, ischemia, and infarction. BioCardia's established catheter delivery technologies enable the potential of therapeutic protein, gene, and cell based therapies currently in development. BioCardia markets a steerable guide catheter product family and is engaged in clinical trials of biotherapeutic agents both independently and with partner organizations. BioCardia is headquartered in South San Francisco, California. For more information, visit the company's website at http://www.biocardia.com.
Contact: Investor Relations, BioCardia, Inc. 650-624-0900, Miranda Peto
###
BioCardia, Inc. announces the issuance of US Patent No. 6,726,654 entitled “System and method for delivering thermally sensitive and reverse-thermal gelation materials”. The patent, describes systems and methods for the delivery of controlled release polymers which change viscosity at different temperature enabling their delivery through catheters in an interventional setting.
BioCardia also announces the issuance of US Patent No. 6,726,242 entitled “Catheter Drug Delivery System and Method for Use”. The patent, describes a means to trigger delivery of a set amount of a therapeutic agent from within a chamber of the heart to a target site in the heart of a patient.
BioCardia is a world leader in the emerging field of biointerventional cardiology, developing locally delivered biotechnology product solutions for patients suffering from heart failure, ischemia, and infarction. BioCardia's established catheter delivery technologies enable the potential of therapeutic protein, gene, and cell based therapies currently in development. BioCardia markets a steerable guide catheter product family and is engaged in clinical trials of biotherapeutic agents both independently and with partner organizations. BioCardia is headquartered in South San Francisco, California. For more information, visit the company's website at http://www.biocardia.com.
Contact: Investor Relations, BioCardia, Inc. 650-624-0900, Miranda Peto
###
Email
Print
SPAM
